Advanz Pharma gets an exclusive right from Alvotech to commercialize five proposed biosimilars in the EU. Alvotech will be responsible for the development and commercial supply
Advanz Pharma will leverage its existing specialty and hospital capabilities in the EU to ensure successful market registration, commercialization, and patient access. The agreement strengthens Advanz’s pipeline of specialty pharmaceuticals to drive mid- and long-term sustainable growth
The agreement also incl. proposed biosimilars to Simponi, Entyvio & 3 additional early-stage undisclosed biosimilar candidates. Alvotech & Advanz Pharma collaborated in Feb 2023 to commercialize AVT23, a proposed biosimilar to Xolair (omalizumab)
Ref: Globenewswire | Image: Alvotech
Related News:- Alvotech Entered into Commercialization Agreement with Advanz Pharma for AVT23, a Proposed Biosimilar to Xolair (omalizumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
